A Phase 1 Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Cosibelimab (Primary)
- Indications B-cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 17 Apr 2019 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 Planned initiation date changed from 3 Jan 2019 to 1 Mar 2019.
- 02 Apr 2018 New trial record